Show simple item record

dc.contributor.authorBurnley-Hall, Nicholas
dc.contributor.authorAbdul, Fairoz
dc.contributor.authorAndroshu, Vitaliy
dc.contributor.authorMorris, Keith
dc.contributor.authorOssei-Gerning, Nicholas
dc.contributor.authorAnderson, Richard
dc.contributor.authorRees, D. Aled
dc.contributor.authorJames, Philip
dc.date.accessioned2017-12-14T13:27:59Z
dc.date.available2017-12-14T13:27:59Z
dc.date.issued2018-01-05
dc.identifier.citationBurnley Hall, N.,Fairoz, A., Androshuk, V., Morris, K., Ossei-Gerning, N., Rees, A.D., James, PE (2018) 'Dietary nitrate supplementation reduces circulating platelet-derived extracellular vesicles in coronary artery disease patients on clopidogrel therapy: A randomised, double-blind, placebo-controlled study', Thrombosis and Haemostasis, 118 (01), pp.112-122en_US
dc.identifier.urihttp://hdl.handle.net/10369/9193
dc.descriptionThis article was published in Thrombosis and Haemostasis on 5 January 2018 (online), available at http://dx.doi.org/10.1160/TH17-06-0394en_US
dc.description.abstractSummary Extracellular vesicles (EVs) are implicated in the pathogenesis of cardiovascular disease (CVD). Specifically, platelet-derived EVs are highly pro-coagulant, promoting thrombin generation and fibrin clot formation. Nitrate supplementation exerts beneficial effects in CVD, via an increase in nitric oxide (NO) bioavailability. Clopidogrel is capable of producing NO-donating compounds, such as S-nitrosothiols (RSNO) in the presence of nitrite and low pH. The aim of this study was to assess the effect of nitrate supplementation with versus without clopidogrel therapy on circulating EVs in coronary artery disease (CAD) patients. In this randomised, double-blind, placebo-controlled study, CAD patients with (n=10) or without (n=10) clopidogrel therapy received a dietary nitrate supplement (SiS nitrate gel) or identical placebo. NO metabolites and platelet activation were measured using ozone-based chemiluminescence and multiple electrode aggregometry. EV concentration and origin were determined using nanoparticle tracking analysis and time-resolved fluorescence. Following nitrate supplementation, plasma RSNO was elevated (4.7±0.8 nM vs 0.2±0.5 nM) and thrombin-receptor mediated platelet aggregation was reduced (-19.9±6.0 U vs 4.0±6.4 U) only in the clopidogrel group compared to placebo. Circulating EVs were significantly reduced in this group (-1.183e11±3.15e10 EVs/mL vs -9.93e9±1.84e10 EVs/mL), specifically the proportion of CD41+ EVs (-2120±728 RFU vs 235±436 RFU) compared to placebo. In vitro experiments demonstrated clopidogrel-SNO can reduce platelet-EV directly (6.209e10±4.074e9 EVs/mL vs 3.94e11±1.91e10 EVs/mL). In conclusion, nitrate supplementation reduces platelet-derived EVs in CAD patients on clopidogrel therapy, increasing patient responsiveness to clopidogrel. Nitrate supplementation may represent a novel approach to moderating the risk of thrombus formation in CAD patients.en_US
dc.description.sponsorshipHealth and Care Research Wales Scholarshipen_US
dc.description.sponsorshipNott Legacy for Thrombosis Researchen_US
dc.language.isoenen_US
dc.publisherSchattauer
dc.relation.ispartofseriesThrombosis and Haemostasis;
dc.subjectExtracellular vesicles, clopidogrel, nitrate, nitrite, nitric oxide.en_US
dc.titleDietary nitrate supplementation reduces circulating platelet-derived extracellular vesicles in coronary artery disease patients on clopidogrel therapyen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1160/TH17-06-0394
dcterms.dateAccepted2017-09-26
rioxxterms.versionAMen_US
rioxxterms.licenseref.startdate2019-01-05
dc.refexceptionOA compliant
rioxxterms.freetoread.startdate2019-01-05


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record